C-SLPI Antibody Detection for Bacterial Infection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for chronic lung diseases like Cystic Fibrosis and COPD are laborious and time-consuming, making it difficult to quickly detect bacterial infections, which delays treatment and exacerbates lung pathology due to the inability to effectively detect C-terminal fragments of SLPI (C-SLPI) produced by the cleavage of SLPI by neutrophil elastase.
Innovation Solution
Development of novel monoclonal antibodies specific to C-SLPI, generated using a peptide hapten linked to a carrier molecule, allowing for the detection and quantification of C-SLPI in patient samples through immunoassays, facilitating rapid diagnosis and monitoring of bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If classical microbiological diagnostic methods are used, then bacterial infection can be detected, but the process is laborious and time-consuming
Solution Approach 1:
The patent extracts the specific biomarker C-SLPI from complex bacterial infection diagnostics. By focusing detection on this single cleavage product generated by neutrophil elastase activity, the method simplifies the diagnostic process while maintaining accuracy, enabling rapid detection without full microbiological culture
Solution Approach 2:
The patent uses C-SLPI as an intermediary marker that indirectly indicates bacterial infection status. Rather than directly detecting bacteria, the assay detects the proteolytic cleavage product of SLPI, which serves as a mediator reflecting the bacterial protease activity in the sample
2Measurement precision
If classical microbiological diagnostic methods are used, then bacterial infection can be detected, but the process is laborious
Solution Approach 1:
The patent extracts the specific biomarker C-SLPI from complex bacterial infection diagnostics. By focusing detection on this single cleavage product generated by neutrophil elastase activity, the method simplifies the diagnostic process while maintaining accuracy, enabling rapid detection without full microbiological culture
Solution Approach 2:
The patent replaces complex mechanical microbiological culture systems with an immunological detection system. Using antibody-based assays (ELISA, Western blot) to detect C-SLPI eliminates the need for prolonged incubation and manual colony counting, reducing procedural complexity while maintaining detection capability
3Reliability
If treatment is delayed due to slow diagnosis, then lung pathology worsens, but rapid detection methods were not available
Solution Approach 1:
The patent enables preliminary detection of bacterial infection through C-SLPI measurement before full clinical deterioration occurs. By detecting the proteolytic cleavage event early, clinicians can initiate treatment sooner, improving outcomes while the simplified assay allows rapid processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies enable rapid and specific detection of C-SLPI, potentially speeding up diagnosis and treatment by providing a more efficient method for identifying bacterial infections and monitoring disease progression in chronic lung diseases, with results showing significant correlation with bacterial infection status and treatment response.
Implementation Method 1
antibodies with a unique specificity for C-SLPI... antibodies, monoclonal antibodies, specific for C-SLPI... specifically binds to the cleaved secretory leukocyte protease inhibitor (C-SLPI)
Data Source
Figure 1~2
Figure 3~4B
Figure 5
AI summary
The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.